The Genetic Nutrition & Functional Medicine Association, in collaboration with GBC and Leopard Gene, recently hosted a high-profile seminar titled “Precision Medicine in Comprehensive Health.” This well-attended event brought together experts across clinical and biotech fields to explore innovations propelling the future of healthcare.
Key themes discussed included:
1. Next-Generation CTC Detection: Exploring clinical use cases and emerging trends in capturing circulating tumor cells.
2. Advancements in Next-Generation Sequencing (NGS): Future applications and technology evolution.
3. Integrated Healthcare Models: Innovative approaches emerging in precision and preventive medicine.
Canada is increasingly embracing precision medicine alongside preventive approaches. GBC showcased its CellBio™ platform, drawing particular praise for its powerful clinical potential. Leveraging patented membrane filtration, the platform delivers over 90% tumor cell recovery, preserving complete cell morphology and enabling downstream applications like NGS, WGS, RT-PCR, cell culture, and anticancer drug sensitivity testing. Fully automated with no need for sample preprocessing, the system enhances downstream accuracy while reducing manual error—and it’s offered in both high-throughput (FX10) and compact (a2000) formats.
Looking ahead, GBC remains committed to advancing medical technology and driving precision medicine globally. We appreciate the enthusiasm and support of all participants in making this event a success.
Key themes discussed included:
1. Next-Generation CTC Detection: Exploring clinical use cases and emerging trends in capturing circulating tumor cells.
2. Advancements in Next-Generation Sequencing (NGS): Future applications and technology evolution.
3. Integrated Healthcare Models: Innovative approaches emerging in precision and preventive medicine.
Canada is increasingly embracing precision medicine alongside preventive approaches. GBC showcased its CellBio™ platform, drawing particular praise for its powerful clinical potential. Leveraging patented membrane filtration, the platform delivers over 90% tumor cell recovery, preserving complete cell morphology and enabling downstream applications like NGS, WGS, RT-PCR, cell culture, and anticancer drug sensitivity testing. Fully automated with no need for sample preprocessing, the system enhances downstream accuracy while reducing manual error—and it’s offered in both high-throughput (FX10) and compact (a2000) formats.
Looking ahead, GBC remains committed to advancing medical technology and driving precision medicine globally. We appreciate the enthusiasm and support of all participants in making this event a success.
){kind=link}